Anamika Manhas
Pancreatic cancer is treated in a multimodal manner, with surgery being a critical component that must be completed in order
to achieve cure potential. In order to achieve curative potential, multimodal treatment for pancreatic cancer must include both
surgery and chemotherapy. Despite developments in surgical procedures and perioperative care, it is still regarded as a high-risk
procedure with significant postoperative morbidity. Several standards have been established to create strong and standardized
outcome references after pancreatic-duodenectomy. The new idea behind using the benchmark concept to surgery is to evaluate
the best possible results in a well-defined low-risk patient group in order to produce meaningful comparative values. More
effective chemotherapy, along with recent advances in surgical skills, has resulted in longer procedures that have pushed the
limits of resectability. Multivisceral resections, with or without resection of major mesenteric arteries, are now being performed
in a growing number of patients, with higher overall survival and/or patient-reported outcomes.